Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma.
Fiche publication
Date publication
août 2018
Journal
Investigational new drugs
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Pr BORG Christophe, Dr NARDIN Charlée
Tous les auteurs :
Nardin C, Borot S, Beaudoin MA, Cattin F, Puzenat E, Gauthier AS, Schillo F, Borg C, Aubin F
Lien Pubmed
Résumé
The recent advent of immune checkpoint inhibitors (ICI), including anti-programmed cell death 1 protein (anti-PD-1) agents has revolutionized the therapeutic approach of metastatic malignancies. Yet, ICI can disrupt immune tolerance resulting in enhanced immune activation in normal tissues with significant toxicity. A dysregulated activation of T-cells directed to normal tissues stands as the main mechanism of immune-related adverse events (irAE). To date, only two cases of immune-related inflammatory orbitopathy related to anti-PD-1 agents have been reported. This rare immune adverse event usually occurred early after ICI initiation. Here, we report the first case of late inflammatory orbitopathy occurring in a melanoma patient treated with pembrolizumab. Consequently, the occurrence of irAE under ICI should be monitored, even late after treatment instauration.
Mots clés
Immune adverse event, Melanoma, Orbitopathy, Pembrolizumab
Référence
Invest New Drugs. 2018 Aug 25;: